Published in Respiratory Therapeutics Week, September 4th, 2006
After discussions with the U.S. Food and Drug Administration (FDA), the company is planning to conduct a 30-day repeat dose animal study prior to filing an investigational new drug (IND) application in 2007.
Nasodine is a proprietary formulation designed to eliminate drug-resistant Staphylococcus aureus in the nasal cavity.
Part of Symbollon's business strategy is to develop a family of safe, broad-spectrum antimicrobial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.